# L4-TICK22-iter1 — cagrilintide-vs-tirzepatide — **KEEP**

Judge: Kimi K3 (Agent J). Did not write this increment. Mood: critic.
File: `src/content/comparisons/cagrilintide-vs-tirzepatide.mdx`
Bar: LOOPS.md L4. Brief: LOOP-TASKS.md #### TICK22 (L67). Implementer note: TICK22.md (not trusted; verified independently).

## Evidence this run (Judge's own fetches, not the note's)

- Efetch 2026-09-02, HTTP 200, 19.7 KB, 314 lines, read in full: PMIDs 34798060 (Lau phase 2), 40544433 (REDEFINE 1), 35658024 (SURMOUNT-1) — `db=pubmed&rettype=abstract&retmode=text`.
- CT.gov v2 2026-09-02: NCT06131437 — `overallStatus: COMPLETED`, enrollment 809 ACTUAL, primary completion 2025-12-08 ACTUAL, completion 2026-01-09 ACTUAL, `hasResults: false`, Phase 3, CagriSema 2.4/2.4 vs tirzepatide 15 mg. Matches file L116 verbatim.
- `git diff --stat HEAD`: 1 file changed, 107 insertions, 109 deletions — modification of an existing URL, no new URL.
- Select-String banned patterns: `22.7`, `Consult`, `76 sources`, `15.22` (hyphen + en-dash), `28.7`, `TRIUMPH`, `<`+digit — **zero hits each**. `63%` ×2 — both are Lau GI adverse events (41%–63% vs 32%), confirmed in the fetched abstract; **not** OSA. `~\$1,000` ×1 — explicitly allowed by the brief. Positive control `cagrilintide|SURMOUNT|REDEFINE`: 56 hits — scan was live, not blind.
- Wrong-id scan: `34739660` (pyridoxine), `37506727` (malaria), `37364590` (Phase 2 T2D CagriSema) — zero hits. Hedge scan: `~9`, `~11`, `~15`, `~22`, `~20`, `2025-2026`, `class-leading` — zero hits. `record` ×1 = "registry record" (benign).
- `Test-Path`: `src/content/peptides/cagrilintide.mdx`, `tirzepatide.mdx`, `comparisons/cagrisema-vs-tirzepatide.mdx` — all exist; internal links resolve, no trailing slash.

## Criterion-by-criterion

1. **Identifiers resolve + topical match — PASS.** All three PMIDs re-fetched by me this run; titles match YAML sources[] exactly. NCTs printed inside the abstracts (NCT03856047, NCT05567796, NCT04184622) match the YAML `nctId` fields — no sibling-trial mixup (REDEFINE 1 40544433, not REDEFINE-2 40544432). NCT06131437 registry claims independently confirmed; **no head-to-head percent quoted** ("This page does not quote a percent from that registry record"). Pyridoxine/malaria PMIDs absent.
2. **Lau phase 2 — PASS.** Trial-product 0.3–4.5 mg 6.0%–10.8% vs placebo 3.0% (ETD 3.0–7.8 pp; P<0.001), 4.5 mg 10.8% vs liraglutide 3.0 mg 9.0% (ETD 1.8; P=0.03), n=706 (100–102 per dose; 99 liraglutide; 101 placebo), 26 wk — every figure matches the abstract. Treatment-policy handled exactly as the abstract allows: "similar reductions were observed" quoted, no invented percent table, and the file says so. No 2.4 mg row. GI 41%–63% vs 32%, nausea 20%–47% vs 18% match.
3. **REDEFINE 1 — PASS.** Treatment-policy −20.4% vs −3.0% (ETD −17.3; 95% CI −18.1 to −16.6; P<0.001), n=3,417, 68 wk, arms (combo / semaglutide 2.4 / cagrilintide 2.4 / placebo) — all match. Attributed to the **combination** throughout (heading "CagriSema is not cagrilintide monotherapy"; "That figure is not a cagrilintide-alone result"); cagrilintide-alone percent correctly flagged as not in the abstract. 22.7% not restored. GI 79.6% vs 39.9% matches.
4. **SURMOUNT-1 — PASS.** Treatment-regimen labelled. −15.0/−19.5/−20.9% (5/10/15 mg) vs −3.1% placebo (P<0.001); ≥20%: 50% (10 mg) and **57% (95% CI 53–61)** (15 mg) vs 3%; AE d/c 4.3/7.1/6.2/2.6 — every figure matches the abstract. Nausea/vomiting percents correctly noted as not published in the abstract; none invented.
5. **Strips — PASS.** Census FAQ (now "This page does not quote a live source census"), consult, ~9%/~11%/~15–22%/~22%/~20%+ hedges, invented GI/nausea tables, 2025–2026 CagriSema timeline, "record/class-leading" — zero residue on scan. `~$1,000+/month` kept per brief instruction; not failed.
6. **Standing bans — PASS.** No new URL (one modified file in diff). No unescaped `<` before a digit — all P-values are `P&lt;0.001`. No TRIUMPH 28.7%, no OSA 63%, no 22.7% anywhere including disavowals. Absence claims are window-dated ("as of 2026-09-02") with the three per-alias PubMed queries named — satisfies the L4 absence rule. Internal links mirror real collection slugs.
7. **YAML — PASS.** Five sources, each with `verifiedAt: '2026-09-02'`; pmid/nctId pairs match fetched records; openFDA source is an access-dated API URL labelled as such; `lastUpdated: 2026-09-02`; no duplicate keys.

## Gaming check

The increment deletes more than it writes (109−/107+) and shrinks a census-and-hedge page into three fetched abstracts plus one registry record, each with its estimand labelled per house rule (trial-product for Lau with the treatment-policy caveat quoted; treatment-policy for REDEFINE 1; treatment-regimen for SURMOUNT-1). The "This page does not invent/quote…" disavowals are stylistically heavy (~8 instances) but each maps to a specific prior fabrication class from the brief and none repeats a banned number — they are guardrails, not trophies. No scope creep: locked TICK19/20/21 files untouched, TICK6-PRICE left parked, no self-marked KEEP, no build run. The FAQ "more clinical evidence" answer now describes the base qualitatively instead of citing counts — the correct repair, since the counts were the fabrication. Nothing on the page outruns the three abstracts and the CT.gov record I fetched.

## Verdict

**KEEP.** Ratchet row may be appended by Conductor. Remaining L4 leftovers per the implementer note (unverified by me, out of this loop's scope): `tirzepatide-vs-retatrutide` hedges, `pemvidutide-vs-semaglutide` census, `amycretin-vs-semaglutide` FAQ census. TICK6-PRICE remains parked on Lucas; W3-M1 still OAuth-blocked.
